Vertex, Inc. (NASDAQ:VERX) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Vertex, Inc. (NASDAQ:VERX) as the company approaches its fiscal ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an announcement. Vertex Minerals Limited has commenced underground ore production at the Reward Gold ...

Amphista Therapeutics has announced the appointment of three new senior leaders: Dr Lisa Butler, Senior Vice President of ...

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...